Definium Therapeutics (DFTX) Research & Development (2021 - 2026)

Definium Therapeutics (DFTX) has 6 years of Research & Development data on file, last reported at $41.5 million in Q1 2026.

• On a quarterly basis, Research & Development rose 77.61% year-over-year to $41.5 million in Q1 2026; TTM through Mar 2026 was $135.8 million, a 76.47% increase from a year earlier, with the FY2025 full-year figure at $117.7 million, up 80.2% from the prior year.
• Research & Development for Q1 2026 stood at $41.5 million, up from $33.5 million in the prior quarter.
• Over the last five years, Research & Development for DFTX reached as high as $41.5 million in Q1 2026 and fell as low as $7.8 million in Q3 2022.
• Historically, Research & Development has averaged $18.4 million across 5 years, with a median of $14.6 million in 2024.
• Across the five-year window, Research & Development declined 18.86% in 2022 and soared 103.54% in 2025, its largest moves.
• Year by year, Research & Development stood at $8.8 million in 2022, then jumped by 30.76% to $11.5 million in 2023, then jumped by 88.45% to $21.8 million in 2024, then jumped by 54.06% to $33.5 million in 2025, then gained by 23.76% to $41.5 million in 2026.
• Per Business Quant data, the three most recent Research & Development figures were $41.5 million in Q1 2026, $33.5 million in Q4 2025, and $31.0 million in Q3 2025.